FGK Clinical Research GmbH, Germany, and Viedoc Technologies AB, headquartered in Sweden, announced today a mutually beneficial partnership. The partnership program, established by Viedoc, is designed to improve trial efficiencies for FGK and its sponsors.
Both companies have worked together for years, making this a natural step forward for both teams.
While the turnaround time has always been fast, this partnership eliminates any business hurdles and allows us to focus 100 percent on our business — running efficient clinical trials, says Martin Krauss, Managing Director at FGK. He continues — This agreement guarantees the continuation of our good relationship and cements our ability to commit to achieving and even exceeding our clients' objectives.
Viedoc is proud to have a partnership agreement with FGK, a CRO with a long and impressive history in the central European market. This partnership is sure to lead to many more well-run, efficient studies for both companies. — Mats Klaar, CEO Viedoc Technologies.
FGK Clinical Research is a full-service CRO based in Munich and Berlin with subsidiaries in Prague, Warsaw and Budapest. Since 2002, FGK has been managing clinical studies of phases I to IV throughout Europe, specializing in the cooperation with small to medium-sized biotech, medical device and pharmaceutical companies by offering a complete range of clinical development and consulting services. For years FGK has been a strong supporter of the Viedoc eClinical suite, helping them to exceed their clients' objectives.
For more information about FGK, visit: www.fgk-cro.com
Viedoc Technologies is a dedicated developer of eClinical systems. The company was founded in Sweden in 2003 by people from the Life Science industry. Today, its clients are clinical research organizations, pharmaceutical, medical device companies, and research institutions working to enhance the lives of millions of people around the world every day.
For more information about Viedoc, visit: www.viedoc.com